ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 904.6 USD | +1.63% |
|
+1.48% | +55.19% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.19% | 815B | |
| +47.26% | 654B | |
| -6.09% | 354B | |
| +21.92% | 337B | |
| +18.40% | 247B | |
| +3.64% | 229B | |
| +12.98% | 219B | |
| +10.86% | 171B | |
| -2.78% | 159B | |
| +1.24% | 122B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Sector Update: Health Care
